Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure

Diabetes Care

Volumn 21, Issue 11, 1998, Pages 1925-1931

  Nauck, Michael A ^a   Sauerwald, Axel ^a   Ritzel, Robert ^a   Holst, Jens J ^b   Schmiegel, Wolff ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIET RESTRICTION; DRUG EFFECT; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; INSULIN TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PEPTIDE ANALYSIS;

AGED; BLOOD GLUCOSE; C-PEPTIDE; CALORIMETRY, INDIRECT; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; FASTING; FATTY ACIDS, NONESTERIFIED; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; POSTPRANDIAL PERIOD; PROINSULIN; PROTEIN PRECURSORS; SULFONYLUREA COMPOUNDS; TRIGLYCERIDES;

EID: 0031724691     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.11.1925     Document Type: Article

References (40)

1. Holst JJ: Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 107:1848-1855, 1994
2. Kreymann B, Williams G, Ghatei MA, Bloom SR: Glucagon-like peptide-1 [7-36]: a physiological incretin in man. Lancet ii:1300-1304, 1987
3. Nauck MA, Bartels E, Ørskov C, Ebert R, Creutzfeldt W: Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 76:912-917, 1993
4. Ørskov C, Holst JJ, Nielsen OV: Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123:2009-2013, 1988
5. Komatsu R, Matsuyama T, Namba M, Watanabe N, Itoh H, Kono N, Tarui S: Glucagonostatic and insulinotropic action of glucagonlike peptide I-(7-36)-amide. Diabetes 38:902-905, 1989
6. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W: Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307, 1993
7. Eissele R, Goke R, Willemer S, Harthus HP, Vermeer H, Arnold R, Goke B: Glucagonlike peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur J Clin In vest 22:283-291, 1992
8. Varndell IM, Bishop AE, Sikri KL, Uttenthal LO, Bloom SR, Polak JM: Localization of glucagon-like peptide (GLP) immunoreactants in human gut and pancreas using light and electron microscopic immunocytochemistry. J Histochem Cytochem 33:1080-1086, 1985
9. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W: Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabertologia 36:741-744, 1993
10. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ: Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673, 1993
11. Willms B, Werner J, Hoist JJ, Ørskov C, Creutzfeldt W, Nauck MA: Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81:327-332, 1996
12. Gutniak MK, Linde B, Hoist JJ, Efendic S: Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17:1039-1044, 1994
13. Nauck MA, Wollschlager D, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Willms B: Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 39:1546-1553, 1996
14. Deacon CF, Johnsen AH, Hoist JJ: Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957, 1995
15. Ritzel R, Øiskov C, Holst JJ, Nauck MA: Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers: dose-response-relationships, Diabetologia 38:720-725, 1995
16. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D: Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 9:129-133, 1986
17. Turner R, Cull C, Holman R: United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124:136-145, 1996
18. Panten U, Schwanstecher M, Schwanstecher C: Sulfonylurea receptors and mechanism of sulfonylurea action. Exp Clin Endocrinol Diab 104:1-9, 1996
19. Göke R, Trautmann ME, Haus E, Richter G, Fehmann HC, Arnold R, Göke B: Signal transmission after GLP-1(7-36)amide binding in RINm5F cells. Am J Physiol 257:G397-G401, 1989
20. Sauerwald A, Nauck MA, Holst JJ, Schmiegel WH: Influence of glucagon-like peptide 1 on fasting hyperglycaemia in NIDDM patients treated with insulin (sulfonylurea failure) (Abstract). Diabetologa 40 (Suppl. 1):A46, 1997
21. Ørskov C, Hoist JJ: Radio-immunoassays for glucagon-like peptides 1 and 2 (GLP-1 and GLP-2). Scand J Clin Lab Invest 47:165-174, 1987
22. Ørskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ: Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide 1 in humans. Diabetes 43:535-539, 1994
23. Hoist JJ, Bersani M, Johnsen AH, Kofod H, Hartmann B, Ørskov C: Proglucagon processing in porcine and human pancreas, J Biol Chem 269:18827-18833, 1994
24. Ferrannini E: The theoretical basis of indirect calorimetry Metabolism (Clin Exp) 37:287-301, 1988
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
26. Weber I, Bach-Esser AK, Bach I, Richter S, Ørskov C, Hoist JJ, Schmiegel W, Nauck MA: Prolonged normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2-diabetic patients (Abstract). Diabetologia 38 (Suppl. 1):A171, 1995
27. Nathan DM, Schreiber E, Fogel H, Mojsov S, Habener JF: Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15:270-276, 1992
28. Göke R, Wagner B, Fehmann HC, Göke B: Glucose-dependency of the insulin stimulatory effect of glucagon-like peptide-1 (7-36) amide on the rat pancreas. Res Exp Med Berl 193:97-103, 1993
29. Qualmann C, Nauck MA, Holst JJ, Ørskov C, Creutzfeldt W: Insulinotropic actions of intravenous glucagon-like peptide-1 (GLP-1) [7-36 amide] in the fasting state in healthy subjects. Acta Diabetol 32:13-16, 1995
30. Shalev A, Holst JJ, Keller U: Effects of glucagon-like peptide 1 (7-36 amide) on whole-body protein metabolism in healthy man. Eur J Clin Invest 27:10-16, 1997
31. Butler PC, Kryshak EJ, Marsh M, Rizza RA: Effect of insulin on oxidation of intracellularly and extracellularly derived glucose in patients with NIDDM: evidence for primary defect in glucose transport and/or phosphorylation but not oxidation. Diabetes 39:1373-1380, 1990
32. Leahy JL, Cooper HE, Deal DA, Weir GC: Chronic hyperglycaemia is associated with impaired glucose influence on insulin secretion: a study in normal rats using chronic in vivo glucose infusions. J Clin Invest 77:908-915, 1986
33. Robertson RP: Type II diabetes, glucose "non-sense", and islet desensitization, Diabetes 38:1501-1505, 1989
34. Nauck MA: Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes. Diabet Med 13 (Suppl.):S39-S43, 1996
35. Nauck MA, Hoist JJ, Willms B, Schmiegel W: Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 105:187-195, 1997
36. Hoist JJ: Degradation of pancreatic peptides: glucagon. In Degradation of Bioactive Substances, Physiology and Pathophysiology. Henriksen JH, Ed. Boca Raton, FL, CRC, 1991, p.167-180
37. Ørskov C, Andreasen J, Hoist JJ: All products of proglucagon are elevated in plasma of uremic patients. J Clin Endocrinol Metab 74:379-384, 1992
38. Baldissera FGA, Hoist JJ: Glicentin 1-61 probably represents a major fraction of glucagon-related peptides in plasma of anaesthetized uraemic pigs. Diabetologia 29:462-467, 1986
39. Mako ME, Starr JI, Rubenstein AH: Circulating proinsulin in patients with maturityonset diabetes. Am J Med 63:865-869, 1977
40. Deacon C, Schleser-Mohr S, Ballmann M, Willms B, Conlon JM, Creutzfeldt W: Preferential release of proinsulin relative to insulin in non-insulin-dependent diabetes mellitus. Acta Endocrinol 119:549-554, 1988